Story Stocks^®

STAAR Surgical (STAA +25%) is the star of the show after this supplier of implantable lenses for the eye guided Q1 revenue well above analyst expectations. Specifically, STAA expects Q1 revenue to be in excess of $90 mln, which would mark its highest revenue quarter since 2Q24.

• Strong Q1 performance was driven primarily by robust sales in China, STAA's largest market, along with continued double-digit growth in the Americas. Higher sales, combined with a significantly improved cost structure, are expected to drive a meaningful improvement in adjusted EBITDA for Q1.
• STAA cautioned that global business conditions remain volatile, with geopolitical and macroeconomic challenges weighing on sales in parts of the Middle East, EMEA, and APAC regions. The company warned that these pressures could persist and potentially spread, creating ongoing uncertainty for sales growth.
• STAA has characterized 2025 as a difficult transition year but expects 2026 to be a year of growth, improving profitability, and progress across its innovation pipeline. The company is benefiting from a broader industry shift toward lens-based refractive procedures and away from laser vision correction surgeries that remove corneal tissue.
• In China, conditions stabilized in 2025 following macroeconomic volatility, with policy support and a stronger stock market positioning the region for a potential rebound. In the US, STAA is seeing momentum despite declining laser vision correction procedures, aided by an expanded age indication for EVO (now approved for myopia treatment in adults aged 21 to 60), increasing its addressable market.

Briefing.com Analyst Insight:

STAA's upbeat Q1 revenue guidance is a notable positive for a stock that has been under significant pressure over the past few years. While the company is not out of the woods yet, particularly given ongoing macro and geopolitical uncertainties, the strong showing in China and continued growth in the Americas suggest that demand trends may be stabilizing. The improved cost structure also adds an important lever for profitability recovery. That said, risks remain elevated, especially with uneven regional performance and limited visibility beyond Q1. Still, after a steep decline from its prior highs, this sharp upside guidance could serve as a catalyst for investors to revisit this former high-growth name, particularly if it can demonstrate more consistent execution in the coming quarters.